September 9, 2020
Preclinical study at Emory University explores relationship between cellular NAD+ and retinal damage.
The study is published in Investigative Ophthalmology & Visual Science finding Niagen® (patented nicotinamide riboside, or NR) prevented light-induced retinal damage in mice.
August 18, 2020
Niagen® (patented nicotinamide riboside) may reduce production of inflammatory cytokines in pilot study of Stage D heart failure patients. A NIH funded study by Cardiology Division and Mitochondria & Metabolism Center at the University of Washington, published in TheJournal of Clinical Investigation, foundthat Niagen supplementation reduced signs of inflammation, specifically inflammatory cytokines in vivo, in a smallgroup of end-stage heart failure patients.
July 8, 2020
Dr. Charles Brenner and a team of scientists from three US universities find that Niagen® decreases Coronavirus replication in animal cells.
The preclinical study results were published July 8 on scientific publishing website bioRxiv.org. The research conducted jointly at the University of Iowa, Oregon Health & Science University, and the University of Kansas previously demonstrated in a preclinical cell model that levels of the coenzyme NAD+ were depleted up to 80% in Coronavirus-infected cells. Consistent with those findings, the new study showed that the loss of NAD+ appeared to disrupt genes involved with cell defense which can impair cells’ innate immune response.
June 30, 2020
ChromaDex shares new preclinical and clinical findings revealing potential of Niagen® across a variety of health conditions, paving the way for further clinical research
The results of multiple new preclinical studies illustrate the multifaceted potential of Niagen® (nicotinamide riboside or NR) in bolstering cellular health to counteract or reduce progression of numerous degenerative conditions. The proven ability of Niagen® to raise NAD+ levels was found to contribute to positive effects in preclinical models of aging, fertility, and circadian rhythms, and in a clinical study on liver function. Several of these studies were made possible through the global ChromaDex External Research Program (CERP), which offers the patented Niagen ingredient to research institutions and universities at no cost.
March 29, 2018
IRVINE, Calif., March 29, 2018 (GLOBE NEWSWIRE) — ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a cutting-edge form of vitamin B3, led by Christopher Martens, PhD and Douglas Seals, PhD, of the Integrative Physiology of Aging Laboratory at the University of Colorado, Boulder (CU Boulder), were reported and published today in the journal, Nature Communications.
AboutNAD is an educational resource created by scientists to explore the cutting-edge research behind the molecule nicotinamide adenine dinucleotide (NAD+) and its vital role in cellular energy. Specifically, we are focused on the recent surge of interest and research surrounding the innovative NAD+ precursor called nicotinamide riboside (NR). Our mission is to provide a balanced look at NAD+’s role in human health by providing the latest educational and scientifically proven content to the public.
We are a world leader in NR and NAD+ research
The active ingredient in ChromaDex’s flagship consumer product TRU NIAGEN® is a unique and proprietary form of nicotinamide riboside (“NR”) that safely and effectively increases nicotinamide adenine dinucleotide (“NAD+”) to support cellular health and resilience. The depth and consistency of the science supporting NR speaks to its value for promoting intrinsic capacity – the body’s ability to cope with physiologic stress.
Four nicotinamide adenine dinucleotide (NAD+) coenzymes are the central catalysts of metabolism that allow us to convert everything we eat into everything we are and everything we do.
Age-Associated Cellular Decline (AACD) is the time-related deterioration in the way our cells function as we age. This often begins in our 40s and accelerates in our 60s. Aging is a complex process involving many physical changes. New advances in scientific discovery have brought a wealth of understanding about why we age, what cellular processes change with age, and the important role cellular health plays in how we age.
By subscribing you agree to our privacy policy.
Copyright © 2020 trulife.ch. All rights reserved.